BELVEDERESI, LAURA
 Distribuzione geografica
Continente #
NA - Nord America 464
EU - Europa 239
AS - Asia 56
AF - Africa 3
Totale 762
Nazione #
US - Stati Uniti d'America 464
IT - Italia 66
UA - Ucraina 45
IE - Irlanda 32
SE - Svezia 32
DE - Germania 19
CN - Cina 17
DK - Danimarca 17
SG - Singapore 17
TR - Turchia 11
FI - Finlandia 9
KR - Corea 9
GB - Regno Unito 7
BE - Belgio 4
CI - Costa d'Avorio 3
FR - Francia 3
AT - Austria 2
NL - Olanda 2
HR - Croazia 1
IN - India 1
VN - Vietnam 1
Totale 762
Città #
Chandler 94
Jacksonville 49
Ashburn 39
Dublin 32
New York 30
Fairfield 29
Boardman 21
Woodbridge 18
Ancona 17
Wilmington 16
Houston 15
Ann Arbor 14
Lawrence 11
Princeton 11
San Mateo 10
Turin 9
Cambridge 8
Centro 7
Singapore 7
Cagliari 6
San Diego 6
Seattle 5
Abidjan 3
Beijing 3
Brussels 3
Des Moines 3
Falconara Marittima 3
Washington 3
Amsterdam 2
Helsinki 2
London 2
Los Angeles 2
Roseto degli Abruzzi 2
Vienna 2
Wuxi 2
Altidona 1
Chengdu 1
Clifton 1
Dong Ket 1
Guangzhou 1
Jiaxing 1
New Bedfont 1
Phoenix 1
Prescot 1
San Francisco 1
Shanghai 1
Waterloo 1
Wuhan 1
Zibo 1
Totale 500
Nome #
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 85
An intronic mutation in MLH1 associated with familial colon and breast cancer. 82
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 77
A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay 75
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 72
Therapeutic Challenges in Tissue Engineering 70
MSH2 missense mutations and HNPCC syndrome: pathogenicity assessment in a human expression system 60
Expectations and psychological issues before genetic counseling: analysis of distress determinant factors 60
Mutazioni nei geni del MMR e sindrome HNPCC: analisi in vitro della patogenicità delle varianti missenso 58
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib 57
Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type 46
null 31
BRCA mutations and gastrointestinal cancers: When to expect the unexpected? 4
Totale 777
Categoria #
all - tutte 4.035
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.035


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202060 1 1 7 0 11 0 9 2 10 0 5 14
2020/2021138 9 15 19 0 15 12 10 12 14 12 13 7
2021/202279 5 17 2 1 0 5 1 5 11 10 1 21
2022/2023239 14 34 12 21 16 31 0 7 44 3 46 11
2023/2024144 25 4 11 12 19 41 1 9 0 3 1 18
2024/202524 24 0 0 0 0 0 0 0 0 0 0 0
Totale 777